Therapeutic antibodies and related products: choosing the right structure for success

被引：9

作者：

Beck, Alain ^{[1
]}

Wagner-Rousset, Elsa ^{[1
]}

Wurch, Thierry ^{[1
]}

Corvaia, Nathalie ^{[1
]}

机构：

[1] Ctr Immunol Pierre Fabre, F-74160 St Julien En Genevois, France

来源：

M S-MEDECINE SCIENCES | 2009年 / 25卷 / 12期

关键词：

MONOCLONAL-ANTIBODIES; HUMAN IGG2; ANTIINFLAMMATORY ACTIVITY; MASS-SPECTROMETRY; GLYCOSYLATION; ISOTYPE; BINDING; HETEROGENEITY; DISCOVERY; DOMAINS;

D O I：

10.1051/medsci/200925121024

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Therapeutic antibodies and related products: choosing the right structure for success Monoclonal antibodies (mAb) and related-products represent the fastest growing class of therapeutics in the biotechnological and pharmaceutical industry. In just as short as 20 years, more than 30 immunoglobulins (IgG) and derivatives have been approved in a wide range of indications (oncology, inflammation and auto-immunity, transplantation, angioplasty, hematology, ophthalmology, viral infections, allergy). The mAb structure toolbox contains mouse, chimeric, humanized and human antibodies from different isotypes (IgG1, 2 and 4), as well as IgG-related products (immunoconjugates, radio-immunoconjugates, Fab fragments, Fc-fusion proteins and peptides, bispecifics). Furthermore from a structural point of view, mAb glycosylation is linked to their production systems and may impact on their effector functions and immunogenicity. Based on the current knowledge, choosing the right antibody format, isotype and glycosylation profile are some of the key issues to address early during the lead selection.

引用

页码：1024 / 1032

页数：9

共 48 条

[21] Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms [J].

Kim, Min-Soo ;

Lee, Seung-Hyun ;

Song, Moo-Young ;

Yoo, Tae Hyoung ;

Lee, Byung-Kyu ;

Kim, Yong-Sung .

JOURNAL OF MOLECULAR BIOLOGY, 2007, 374 (05) :1374-1388

[22] CONTINUOUS CULTURES OF FUSED CELLS SECRETING ANTIBODY OF PREDEFINED SPECIFICITY [J].

KOHLER, G ;

MILSTEIN, C .

NATURE, 1975, 256 (5517) :495-497

[23] Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange [J].

Kolfschoten, Marijn van der Neut ;

Schuurman, Janine ;

Losen, Mario ;

Bleeker, Wim K. ;

Martinez-Martinez, Pilar ;

Vermeulen, Ellen ;

den Bleker, Tamara H. ;

Wiegman, Luus ;

Vink, Tom ;

Aarden, Lucien A. ;

De Baets, Marc H. ;

van De Winkel, Jan G. J. ;

Aalberse, Rob C. ;

Parren, Paul W. H. I. .

SCIENCE, 2007, 317 (5844) :1554-1557

[24] When binding is enough: nonactivating antibody formats [J].

Labrijn, Aran F. ;

Aalberse, Rob C. ;

Schuurman, Janine .

CURRENT OPINION IN IMMUNOLOGY, 2008, 20 (04) :479-485

[25] Human IgG2 Antibody Disulfide Rearrangement in Vivo [J].

Liu, Y. Diana ;

Chen, Xiaoyu ;

Enk, Jian Zhang-van ;

Plant, Matt ;

Dillon, Thomas M. ;

Flynn, Gregory C. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (43) :29266-29272

[26] ANTIGEN-SPECIFIC HUMAN-ANTIBODIES FROM MICE COMPRISING 4 DISTINCT GENETIC MODIFICATIONS [J].

LONBERG, N ;

TAYLOR, LD ;

HARDING, FA ;

TROUNSTINE, M ;

HIGGINS, KM ;

SCHRAMM, SR ;

KUO, CC ;

MASHAYEKH, R ;

WYMORE, K ;

MCCABE, JG ;

MUNOZOREGAN, D ;

ODONNELL, SL ;

LAPACHET, ESG ;

BENGOECHEA, T ;

FISHWILD, DM ;

CARMACK, CE ;

KAY, RM ;

HUSZAR, D .

NATURE, 1994, 368 (6474) :856-859

[27] Fully human antibodies from transgenic mouse and phage display platforms [J].

Lonberg, Nils .

CURRENT OPINION IN IMMUNOLOGY, 2008, 20 (04) :450-459

[28] PHAGE ANTIBODIES - FILAMENTOUS PHAGE DISPLAYING ANTIBODY VARIABLE DOMAINS [J].

MCCAFFERTY, J ;

GRIFFITHS, AD ;

WINTER, G ;

CHISWELL, DJ .

NATURE, 1990, 348 (6301) :552-554

[29] Certolizumab pegol [J].

Melmed, Gil Y. ;

Targan, Stephan R. ;

Yasothan, Uma ;

Hanicq, Delphine ;

Kirkpatrick, Peter .

NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (08) :641-642

[30] A multicenter, randomized, open-label, therapeutic, and exploratory trial to evaluate the tolerability and efficacy of platelet glycoprotein IIb/IIIa receptor blocker (Clotinab™) in high-risk patients with percutaneous coronary intervention [J].

Moon, Jae-Youn ;

Kim, Weon ;

Kim, Ju Han ;

Ahn, Youngkeun ;

Jeong, Myung Ho ;

Kim, Young-Hak ;

Hong, Myeong-Ki ;

Park, Seong-Wook ;

Park, Seung-Jung ;

Park, Sungha ;

Ko, Young-Guk ;

Choi, Donghoon ;

Jane, Yangsoo .

YONSEI MEDICAL JOURNAL, 2008, 49 (03) :389-399

← 1 2 3 4 5 →